MetaVia (NASDAQ:MTVA) Raised to Sell at Wall Street Zen

MetaVia (NASDAQ:MTVA) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday.

MTVA has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of MetaVia in a report on Monday, May 18th. Weiss Ratings restated a “sell (e+)” rating on shares of MetaVia in a report on Friday, April 24th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $20.00.

MetaVia Stock Performance

NASDAQ MTVA opened at $1.60 on Friday. The company has a market cap of $8.26 million, a P/E ratio of -0.31 and a beta of 0.92. The company has a fifty day simple moving average of $1.89 and a 200 day simple moving average of $3.37. MetaVia has a 12-month low of $0.97 and a 12-month high of $19.03.

MetaVia (NASDAQ:MTVA) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.03). Sell-side analysts predict that MetaVia will post -2.78 EPS for the current year.

Institutional Trading of MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC bought a new stake in MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia at the end of the most recent reporting period. Institutional investors own 1.37% of the company’s stock.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.